A Strategic Handshake: Astria Therapeutics Licenses Key Drug to BioCryst, Redefining Focus
Shareholder Alert: Are Your Investments Being Undervalued in Recent Mergers?
BioCryst Pharmaceuticals Strikes Strategic $700 Million Deal, Propelling Astria's HAE Pipeline and Strengthening Its Own Focus